Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Study Summary

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Conditions

Cushing Syndrome

Interventions / Drugs

relacorilant

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment125 participants

Primary Completion—

Lead SponsorCorcept Therapeutics

Data Retrieved2026-04-11 04:10:22.666670+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.